GNA11 and neoplasm: Additionally, they found that patients with GNA11-mutant tumours had poorer disease-specific survival (60.0 vs. 121.4 months p-value = 0.03) and OS (50.6 vs. 121.4 months p-value = 0.03), than those with tumours lacking GNA11 mutations.